Get it on Google Play

Odyssey Therapeutics to present OD-001 ulcerative colitis data at UEG Week

October 6, 2026 8:00 AM EDT Send to a Friend
Odyssey Therapeutics, Inc. (Nasdaq: ODTX) announced that additional Phase 2a induction data for its drug candidate OD-001 in moderate to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login